Adcetris (brentuximab vedotin)

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

While response rates were similar, PFS was shorter. These findings suggest that BV remains a potential therapeutic option in this patient population and merits further prospective investigation.

The patient achieved a partial response with methotrexate but discontinued after ~12 months due to elevated transaminases. Following treatment with bexarotene then gemcitabine, CHOP chemotherapy was initiated in December 2019, but, after a period of partial skin response, the patient relapsed with progression of skin lesions...Disease progression in the skin occurred in December 2020; mogamulizumab was continued, and the patient achieved remission with the addition of etoposide and prednisone in August 2021...In October 2022, the patient was diagnosed with large cell CD30+ transformation, and the therapeutic approach was changed to extracorporeal photopheresis, brentuximab vedotin, and topical steroids. The patient died in February 2023 due to sepsis. Our experience adds to the limited evidence that mogamulizumab may be continued in combination with etoposide following disease progression in patients with MF with blood involvement; however, more research is needed on the efficacy and safety of this approach.

P1/2, N=40, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Dec 2025

P2, N=100, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Jun 2026 --> Jun 2027

The patient received brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone (BV-CHP) chemotherapy following multidisciplinary review and showed marked improvement. This case illustrates the diagnostic challenge of ALK-positive ALCL presenting as a recurrent axillary abscess. Early recognition and histopathological evaluation of atypical or non-resolving abscesses are essential for timely diagnosis and effective treatment, ultimately improving patient outcomes.

This understanding provides a strong rationale for COO- and TME-guided therapeutic strategies, such as combining the anti-CD30 antibody-drug conjugate brentuximab vedotin with immunomodulatory agents. This report elucidates the enigma of CD30 and outlines a path towards personalized medicine for DLBCL.

P3, N=304, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P3, N=238, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026

He commenced first-line systemic therapy with methotrexate, but had no response. He was switched to brentuximab vedotin and has received eight cycles with partial response...Approach to mycosis fungoides in children: consensus-based recommendations. J Am Acad Dermatol 2024; 91: 1078-85).

P2, N=23, Not yet recruiting, City of Hope Medical Center

A carefully staged treatment plan was employed, beginning with corticosteroids and etoposide, followed by liposomal mitoxantrone and the CD30-targeted antibody-drug conjugate brentuximab vedotin. The clinical course highlights the necessity of maintaining a high index of suspicion for lymphoma in refractory joint infections and demonstrates that individualized, stepwise therapy can achieve remission even in critically ill patients with aggressive ALCL. These findings provide valuable insights for improving the diagnosis and management of lymphoma cases that mimic infectious diseases.